About Medeon Biodesign
Medeon Biodesign is a company based in Taipei (Taiwan) founded in 2012. Medeon Biodesign operates in a competitive market with competitors including Endologix, Endoron Medical, Trivascular, Altura Medical and Aptus Endosystems, among others.
- Headquarter Taipei, Taiwan
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website medeonbio.com
- Legal Name Medeon Biodesign, Inc.
- Annual Revenue$419.43 M43.24as on Dec 31, 2025
- Net Profit-$668.06 M17.06as on Dec 31, 2025
- EBITDA-$615.15 M21.83as on Dec 31, 2025
People of Medeon Biodesign
1 people are tracked at Medeon Biodesign (1 in leadership).
| Name | Role | Group |
|---|---|---|
Yue Teh Jang | Chairman & CEO | Leadership |
Complete people profiles for Medeon Biodesign
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Medeon Biodesign
Medeon Biodesign is a publicly listed company on the TPEX with ticker symbol 6499 in Taiwan, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 2016
- Listed onTT: 6499
- Listed entityMedeon Biodesign, Inc.
- Exchange sectorElectronic technology
- ISINTW0006499007
- Share price81.00 TWD (+0.5% on the day) · 2026-10-12
- Market capitalisation7,790,867,479.00 TWD
- EPS (diluted, trailing year)-5.90 TWD
- Volume (last session)198,645
Financials of Medeon Biodesign
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 419.4M TWD | -668.1M TWD | -615.1M TWD |
| 2024 | 292.8M TWD | -805.5M TWD | -787.0M TWD |
| 2023 | 196.3M TWD | -1.20B TWD | -743.9M TWD |
| 2022 | 298.3M TWD | -433.8M TWD | -424.0M TWD |
| 2021 | 69.0M TWD | 2.08B TWD | -436.6M TWD |
Detailed financial statements for Medeon Biodesign
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Medeon Biodesign
Medeon Biodesign operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Endologix, Endoron Medical, Trivascular, Altura Medical and Aptus Endosystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| endologix.com | 1992 | Irvine, United States | – | 488 | Minimally invasive treatments for aortic disorders are developed and manufactured. | |
| endoronmedical.com | 2019 | Kfar Saba, Israel | $15M | – | Endovascular fixation devices for cardiovascular stent grafts are manufactured. | |
| trivascular.com | 1998 | Santa Rosa, United States | $260.95M | 307 | Designs and manufactures for endovascular aortic repair equipment | |
| alturamedical.com | 2008 | Menlo Park, United States | $49.5M | – | Endovascular devices for aortic aneurysms are developed. | |
| aptusendo.com | 2002 | Sunnyvale, United States | $70M | 63 | Endograft anchoring systems for aortic aneurysms are developed. | |
| remonmedical.com | 1997 | Caesarea, Israel | $26M | – | Miniature implants are developed to monitor intra-aneurysm pressure and hemodynamics. | |
| endovastec.com | 2012 | Shanghai, China | – | – | Medical devices for treating aortic diseases are developed. | |
| nellix.com | 1994 | Palo Alto, United States | $18.2M | – | Medical device catering less invasive treatment of Abdominal Aortic Aneurysms | |
| emblok.com | 2013 | Kalamazoo, United States | $19.75M | – | Embolic protection devices are developed for TAVR procedures. | |
| jotec.com | 2000 | Hechingen, Germany | – | 451 | Stents and Grafts for Aortic and Peripheral arterial disease |
Detailed competitors of Medeon Biodesign
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Medeon Biodesign
Websites that share an audience with Medeon Biodesign (medeonbio.com).
Websites whose visitors overlap most with Medeon Biodesign. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Similar companies to Medeon Biodesign
10 companies that operate in the same segment as Medeon Biodesign (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Medeon Biodesign
Medeon Biodesign was founded in 2012.
Medeon Biodesign is headquartered in Taipei, Taiwan.
Yue Teh Jang is the current CEO of Medeon Biodesign.
Medeon Biodesign was founded in 2012 in Taipei, Taiwan, within the medical devices sector. Devices for interventional cardiovascular procedures, including percutaneous coronary intervention and transcatheter aortic valve implantation, are developed to address coronary artery disease with reduced invasiveness compared to traditional open-heart surgery. Minimally invasive tools for laparoscopic surgery, involving incisions of 3mm to 15mm, are also created to support procedures with fewer complications and shorter recovery periods.
Medeon Biodesign's top competitors include Endologix, Trivascular and Shanghai MicroPort Endovascular MedTech.
Yes, Medeon Biodesign is publicly traded on TPEX under the ticker symbol 6499.